FDA Classifies Spectra Sodium Chloride Flush Ampule Recall as Class I in September 2026: Downstream Kit Corrections Cascade Across the Supply Chain

Summary: In September 2026, the U.S. Food and Drug Administration (FDA) classified the recall of 0.9% Sodium Chloride Injection, USP, 10 mL flush ampules by Spectra Medical Devices (operating entity: Elevaris Medical Devices) as a Class I recall, the most serious category. The FDA stated that continued use of the device may cause serious injury or death. This classification signals that the Agency considers the risk high enough to require healthcare facilities to immediately inventory and dispose of products in use and in stock.

Product and Intended Use

The affected product is 0.9% Sodium Chloride Injection, USP, 10 mL ampules, indicated for flushing compatible intravenous line systems and indwelling intravascular access devices. Product and catalog codes published by the FDA include AMPUL10MLK, 1510-1 (single ampule) and 1510-2 (carton). The complete list of affected lots is the list provided by the FDA. In other words, the products named in this action are not infusion pumps or catheters, but the most basic flush saline ampule.

Root Cause Lies Upstream

The reason for the recall is not Spectra's own filling operations but an upstream supplier. Spectra is removing flush products manufactured by Huons Co., Ltd. of Korea. Huons initiated a voluntary recall of 0.9% Sodium Chloride Injection, USP after an FDA inspection of its manufacturing facility identified quality issues. According to the FDA, if sterility is compromised, viable microorganisms, endotoxins and/or foreign matter generated during manufacturing may be exposed to patients, potentially triggering systemic inflammatory response, infection, microthrombosis and organ failure, particularly in high-risk patient populations.

Company Actions and Regulatory Process

• On July 6, 2026, Spectra Medical Devices issued a letter to all affected customers requiring immediate inventory checks and the disposal or return of unused affected flush ampules.
• For products already in distribution, downstream customers were instructed to dispose of or return the product as well.
• Customers were also asked to remain vigilant and to identify and report potential patient health issues that may be associated with this batch of ampules.
• As of July 6, the company had not reported any serious injuries or deaths related to this issue.
• From a regulatory standpoint, the recall was first communicated to the public as an early alert and was subsequently formally classified as a Class I recall in the September update.

Risk Spreads to Kits and Convenience Trays

The impact of this single supply chain did not stop at the flush ampules themselves; it spread downstream to convenience kits and surgical trays. According to the FDA Medical Device Safety page, AVID Medical was listed in September 2026 as issuing a correction for kits containing Huons sodium chloride ampules, covering models such as continuous nerve block trays, single-shot epidural trays, basic biopsy trays and general imaging biopsy trays. Becton Dickinson also issued corrections in August 2026 for kits and procedure trays containing the recalled sodium chloride ampules.

At a further tier, other products from the same supplier produced knock-on effects. Medline issued a correction in August 2026 for convenience kits containing Huons lidocaine and bupivacaine (in dextrose injection) components, while Medical Action Industries and Argon Medical issued corrections in August and July 2026 respectively for kits containing Spectra Medical Devices lidocaine ampules. Taken together, one upstream sterility assurance failure ultimately evolved into multiple correction actions spanning several assemblers and multiple product lines.

How Kit-Type Products Should Be Handled

For kit assemblers such as AVID Medical, the FDA did not prescribe scrapping the entire kit. The Agency required that use of the sodium chloride ampule within the kit be stopped, and that kits containing the ampule be inventoried and quarantined until new labels are printed and affixed to all kits; the remaining components in the kit may continue to be used. In its August 10 customer letter, AVID Medical provided a label template and required that the warning label be placed where it is visible to the end user and does not obscure other critical product information. The company also stated that sodium chloride ampules in the kits may expose patients to viable microorganisms, endotoxins and foreign matter, with higher risk in critically ill patients or in procedures near vulnerable organs such as the spinal cord, potentially inducing abscess formation and subsequent paralysis.

Information Boundaries

It should be noted that the figures and model numbers above come from FDA public pages and manufacturer customer letters; the affected lot numbers, distribution scope and correction methods differ between products. Companies conducting self-checks against this information should rely on the official lists and their own supplier notifications, and should not directly apply the correction scope of one model to other products.

Sources and Applicability Notes

• Source: U.S. Food and Drug Administration (FDA) - Sodium Chloride Flush Recall: Spectra Medical Removes Sodium Chloride Injection USP Ampules, published 2026-09-18; https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/sodium-chloride-flush-recall-spectra-medical-removes-sodium-chloride-injection-usp-ampules
• U.S. Food and Drug Administration (FDA) - Convenience Kit Correction: AVID Medical Issues Correction for Kits Containing Huons Sodium Chloride Ampules, published 2026-09-02; https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/convenience-kit-correction-avid-medical-issues-correction-kits-containing-huons-sodium-chloride
• U.S. Food and Drug Administration (FDA) - Medical Device Safety (recalls and early alerts listing); https://www.fda.gov/medical-devices/medical-device-safety
• U.S. Food and Drug Administration (FDA) - Enforcement Report: Huons Co., Ltd. Saline and Lidocaine Recall (Event 98724); https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=98724
• U.S. Food and Drug Administration (FDA) - Enforcement Report: Spectra Medical Devices Sodium Chloride Flush Recall (Event 98777); https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=98777
• Verification scope and access date: the FDA Medical Device Safety page, the Spectra Medical recall notice page, the AVID Medical kit correction notice page and the two Enforcement Report entries listed above were verified; the access date was October 7, 2026.
• Applicability statement: this article is an interpretation of publicly available U.S. FDA regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application; recall scope, lot numbers and disposition requirements are governed by the official texts, and the information may change with subsequent official updates.

AIMEILI Regulatory Interpretation

This case is a textbook example of a component-level quality failure escalating into a Class I finished-device recall and then propagating across multiple legal manufacturers. Several points deserve attention from a regulatory affairs perspective.

• Class I classification threshold: FDA assigns Class I when there is a reasonable probability that use of or exposure to the device will cause serious adverse health consequences or death. Here, the loss of sterility assurance - potential exposure to viable microorganisms, endotoxins or foreign matter - was sufficient to meet that threshold, even though the product is a low-risk, commodity-type saline flush rather than a high-risk implant.
• Legal manufacturer accountability for outsourced components: A kit assembler or finished-device manufacturer remains responsible for the conformity of purchased components. Under 21 CFR 820 and ISO 13485 Clause 7.4, supplier qualification, incoming inspection, change control and ongoing supplier monitoring are not administrative formalities; they are the control points that would have detected an upstream sterility failure earlier.
• Component recall versus finished device recall: The FDA action against the ampule manufacturer is distinct from the corrections imposed on kit assemblers. Assemblers were permitted to retain the rest of the kit and relabel, which is an unusual and instructive remedy: it shows that FDA tailors corrective action to risk rather than defaulting to total product destruction.
• Relabeling as a controlled activity: The requirement to print and affix new labels, in a position visible to the end user and without obscuring other critical information, is effectively a labeling correction under controlled conditions. It must be documented, verified and traceable, and the effectiveness of the field action must be checked.
• Vigilance and notification obligations: Recalls and field safety corrective actions of this nature trigger reporting duties in multiple jurisdictions. Under EU MDR, for example, manufacturers must submit a field safety corrective action and field safety notice through the vigilance system, and distributors must cooperate and pass information down the supply chain.
• Traceability to lot level: The ability to identify exactly which kits and trays contain which ampule lots within hours, not weeks, is the decisive capability in this kind of event. Where traceability is incomplete, the correction scope must be broadened.

Business Impact for Manufacturers, Distributors and Regulatory Affairs Teams

• Inventory and logistics cost: Quarantine, reverse logistics, relabeling and replacement supply create immediate operational cost, and in a multi-product cascade the affected SKUs multiply quickly.
• Supply continuity: A single-source ampule supplier can interrupt an entire kit portfolio. Dual sourcing, buffer stock and validated alternative suppliers are now a commercial resilience question, not only a quality question.
• Contract and liability exposure: Supply agreements should address notification timelines, indemnification, recall cost allocation and cooperation obligations when an upstream supplier is the root cause.
• Customer and clinician communications: Hospitals need unambiguous instructions - which lot, which kit, what to discard, what may be retained. Ambiguity increases the risk of continued use and of adverse events.
• Audit and inspection readiness: Following a Class I event in the same supply chain, regulators and notified bodies are likely to scrutinize supplier audit records, CAPA effectiveness, incoming inspection rationale and risk management files at downstream firms.
• Post-market surveillance data: Complaint and trend data should be reviewed for any signals associated with affected kit lots, including infection, abscess or inflammatory presentations, even where causality is not yet established.
• Practical self-check for companies: confirm whether any purchased ampule, kit or tray contains Huons or Spectra Medical Devices components; reconcile lot numbers against the official FDA lists; verify that quarantine is physically and systemically enforced; confirm that notifications reached all consignees; and document the decision logic and any corrective actions taken.

Sources: U.S. Food and Drug Administration (FDA), 2026-09-18 and 2026-09-02.